

Supporting Information

Supplementary results

**This appendix was part of the submitted manuscript and has been peer reviewed.
It is posted as supplied by the authors.**

Appendix to: Stafford F, Dore GJ, Clackett S, et al. Prescribing of direct-acting antiviral therapy by general practitioners for people with hepatitis C in an unrestricted treatment program. *Med J Aust* 2021; doi: 10.5694/mja2.51204.

Table. Characteristics of patients and treatment regimens prescribed for people with chronic hepatitis C infections who commenced direct-acting antiviral (DAA) therapy, March 2016 – March 2020, by prescriber speciality

Characteristic	All prescribers	General practitioners	Specialists	Other prescribers
Number of patients	82 694	36 098	42 585	4011
Age at initiation (years)				
Mean (SD)	48 (12)	46 (12)	50 (12)	46 (12)
Median (IQR)	49 (39–57)	46 (37–55)	51 (41–58)	46 (37–55)
Sex				
Women	26 423 (32%)	11 341 (31%)	13 744 (32%)	1338 (33%)
Men	56 253 (68%)	24 751 (69%)	28 829 (68%)	2673 (67%)
Unknown	18 (< 1%)	6 (< 1%)	12 (< 1%)	0
HIV co-infection				
Yes	1436 (2%)	465 (1%)	878 (2%)	93 (2%)
No	81 258 (98%)	35 633 (99%)	41 707 (98%)	3918 (98%)
Residence remoteness				
Urban	53 384 (65%)	23 329 (65%)	28 230 (66%)	1825 (46%)
Regional	27 992 (34%)	12 156 (34%)	13 700 (32%)	2136 (53%)
Unknown	1318 (2%)	613 (2%)	655 (2%)	50 (1%)
Prescribed DAA regimen				
Short regimens*	11 488 (14%)	5933 (16%)	4708 (11%)	847 (21%)
Medium regimens†	59 926 (72%)	26 809 (74%)	30 308 (71%)	2809 (70%)
Long regimens‡	8242 (10%)	2188 (6%)	5822 (14%)	232 (6%)
Other regimens	3040 (4%)	1170 (3%)	1747 (4%)	123 (3%)

HIV = human immunodeficiency virus; IQR = interquartile range; SD = standard deviation.

* Eight weeks: ledipasvir/sofosbuvir or glecaprevir/pibrentasvir.

† Twelve weeks: ledipasvir/sofosbuvir, sofosbuvir/daclatasvir, elbasvir/grazoprevir, sofosbuvir/velpatasvir, or glecaprevir/pibrentasvir.

‡ Twenty-four weeks: ledipasvir/sofosbuvir or sofosbuvir/daclatasvir; or 16 weeks: glecaprevir/pibrentasvir or 16 weeks elbasvir/grazoprevir; or 12 weeks: sofosbuvir/velpatasvir/voxilaprevir.

Figure. Quarterly number (A) and proportion (B) of prescribers who prescribed direct-acting antiviral therapy for the first time (new prescribers), March 2016 – March 2020, by prescriber type

